Lisinopril vs Amlodipine: Real-World Evidence Comparison

What Are Lisinopril and Amlodipine, and How Do They Lower Blood Pressure?

Lisinopril blocks angiotensin-converting enzyme, preventing the conversion of angiotensin I to the vasoconstrictor angiotensin II. Amlodipine blocks voltage-gated L-type calcium channels in vascular smooth muscle, causing direct arterial dilation. Both drugs are generic, once-daily oral agents and appear on the World Health Organization Model List of Essential Medicines. Their mechanisms are complementary enough that they are frequently prescribed together.

Lisinopril: Mechanism and Pharmacokinetics

Lisinopril is water-soluble and is not hepatically metabolized, which simplifies drug-drug interaction risk. It reaches peak plasma concentration in about 7 hours and has a half-life of roughly 12 hours, though its tissue ACE-binding duration extends antihypertensive effect across 24 hours. The FDA approved lisinopril for hypertension, heart failure, and acute MI with left ventricular dysfunction. Dose range spans 2.5 mg to 40 mg once daily depending on the indication.

Renal excretion means dose reduction is needed when eGFR falls below 30 mL/min/1.73 m². Serum potassium and creatinine should be monitored within 1-2 weeks of initiation, particularly in patients with baseline CKD or concurrent NSAID use.

Amlodipine: Mechanism and Pharmacokinetics

Amlodipine has an exceptionally long half-life of 35-50 hours, producing smooth 24-hour blood pressure control with once-daily dosing and minimal peak-trough variation. Hepatic metabolism via CYP3A4 is the primary clearance route, so dose adjustment is recommended in severe hepatic impairment rather than renal impairment. The FDA approved amlodipine for hypertension and chronic stable or vasospastic angina.

Peripheral edema, the most common adverse effect, results from precapillary arteriolar dilation without proportional venodilation. Elevating the legs or reducing the dose to 5 mg may partially mitigate this. Switching from amlodipine to an ARB-based regimen is sometimes pursued when edema is intolerable.

ALLHAT: The Landmark Head-to-Head Data

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) remains the largest randomized hypertension outcomes trial ever conducted. Published in JAMA 2002 (N=33,357), it randomized high-risk hypertensive patients aged 55 and older to chlorthalidone, amlodipine, or lisinopril. [1]

Primary Outcome

The primary outcome was combined fatal coronary heart disease and non-fatal MI. Amlodipine and lisinopril both performed comparably to chlorthalidone on this endpoint. Relative risk for combined CHD was 0.98 (95% CI 0.90-1.07) for amlodipine vs chlorthalidone and 1.00 (95% CI 0.91-1.08) for lisinopril vs chlorthalidone. Neither drug differed significantly from the thiazide-type diuretic on the primary endpoint.

Secondary Outcomes Where the Drugs Diverged

Lisinopril was associated with higher rates of stroke compared with chlorthalidone (relative risk 1.15, P<0.02) and with amlodipine, partly explained by a 2 mmHg higher systolic BP in the lisinopril arm. This difference was more pronounced in Black participants, where lisinopril's systolic BP control was approximately 4 mmHg inferior. The ALLHAT investigators noted: "Thiazide-type diuretics should be preferred for most patients. For high-risk patients requiring additional drugs, a CCB or ACE inhibitor may be added." [1]

Heart failure hospitalization was higher in the amlodipine arm vs chlorthalidone (relative risk 1.38, P<0.001), a finding widely attributed to amlodipine's lack of neurohormonal modulation rather than direct cardiotoxicity.

Subgroup Findings in Diabetes

Among the 36% of ALLHAT participants with diabetes at baseline, lisinopril and amlodipine performed similarly on the primary CHD outcome. Both were inferior to chlorthalidone on combined cardiovascular disease outcomes in diabetic patients in this trial, though this conflicts with dedicated nephropathy trial data (see the CKD section below).

ASCOT-BPLA: Amlodipine-Based Strategy vs Atenolol-Based Strategy

The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) randomized 19,257 hypertensive patients with at least three additional cardiovascular risk factors to amlodipine 5-10 mg (with perindopril added as needed) vs atenolol 50-100 mg (with bendroflumethiazide added as needed). Published in The Lancet 2005, the trial was stopped early at a median 5.5 years. [2]

Stroke and Cardiovascular Death

The amlodipine-based arm produced a 23% relative reduction in fatal and non-fatal stroke (P<0.0003) and a 24% reduction in cardiovascular mortality (P=0.0010) compared with the atenolol-based arm. Total coronary events were reduced by 13% (P=0.0070). Although this trial compared drug strategies rather than lisinopril against amlodipine head-to-head, it established that CCB-based regimens with ACE inhibitor add-on outperform beta-blocker plus thiazide strategies for cardiovascular outcomes.

Metabolic Advantages of the ACE Inhibitor Component

New-onset diabetes was 30% lower in the amlodipine/perindopril arm (P<0.0001), a finding attributed largely to the ACE inhibitor perindopril rather than to amlodipine itself. This points to a class effect of ACE inhibitors, including lisinopril, in preserving insulin sensitivity. The ASCOT data reinforced the AHA/ACC 2017 guideline recommendation that an ACE inhibitor plus a CCB is a preferred two-drug combination for most patients who need combination therapy. [3]

Renal and Diabetic Nephropathy Outcomes

Lisinopril has a distinct advantage in patients with diabetic nephropathy or proteinuric CKD. The EUCLID trial and, more directly, the landmark Captopril Trial (Lewis et al., NEJM 1993, N=409) established that ACE inhibitor therapy reduces the risk of doubling serum creatinine and the composite of death, dialysis, or transplantation in type 1 diabetic nephropathy by 50% compared with placebo. [4] Lisinopril carries the same class benefit and is frequently used in this population.

Amlodipine and the Kidney

Amlodipine does not reduce proteinuria and has no specific indication for nephroprotection. In the AASK trial (African American Study of Kidney Disease), ramipril (another ACE inhibitor) significantly slowed GFR decline vs amlodipine in hypertensive nephrosclerosis (P=0.006 for the composite renal outcome). [5] This means that in CKD patients with significant proteinuria (above 300 mg/day), ACE inhibitors such as lisinopril are preferred over amlodipine as first-line agents.

When Amlodipine Is Preferred in CKD

In non-proteinuric CKD or advanced CKD (eGFR <30) where ACE inhibitor-related hyperkalemia becomes a barrier, amlodipine is a safe alternative for blood pressure control. No dose adjustment is needed based on renal function alone.

Blood Pressure Efficacy Across Populations

Black Patients

ALLHAT found that lisinopril controlled blood pressure approximately 4 mmHg less effectively in Black participants compared with chlorthalidone, while amlodipine achieved comparable systolic control to chlorthalidone across racial subgroups. [1] The AHA/ACC 2017 guideline states: "For Black adults, initial antihypertensive treatment with a thiazide-type diuretic or CCB is recommended." [3] Lisinopril monotherapy is a second-line choice in this population unless diabetes or proteinuric CKD is present.

Older Adults

Both drugs are appropriate for patients over 65. The JNC 8 panel did not distinguish between ACE inhibitors and CCBs by age for initial therapy. Amlodipine's long half-life can be an advantage in older patients with inconsistent pill-taking habits.

Women of Childbearing Potential

Lisinopril is FDA category X in pregnancy and must be discontinued before conception or as soon as pregnancy is confirmed. Amlodipine is category C. Neither drug is a first choice during pregnancy; methyldopa, labetalol, and nifedipine are preferred per ACOG guidelines. [6]

Side Effect Profiles: A Practical Comparison

Lisinopril Side Effects

Dry cough affects 10-15% of patients and is a class effect of ACE inhibitors caused by bradykinin accumulation. It is the most common reason for switching to an ARB such as losartan or valsartan. Angioedema occurs in approximately 0.1-0.7% of patients and is more common in Black patients (rate up to 4x higher). Hyperkalemia is clinically meaningful when lisinopril is combined with potassium-sparing diuretics, potassium supplements, or in patients with eGFR <45. First-dose hypotension can occur in volume-depleted patients.

Amlodipine Side Effects

Peripheral edema is dose-dependent, affecting roughly 3% at 5 mg and up to 10% at 10 mg. Flushing and headache occur in a smaller proportion, typically resolving within the first 2-4 weeks of therapy. Amlodipine does not cause cough or angioedema. Gingival hyperplasia is a rare but recognized effect seen mainly at high doses with prolonged use.

Drug Interactions

Lisinopril interacts with NSAIDs (reduced antihypertensive effect and increased nephrotoxicity risk), potassium-sparing agents, lithium, and sacubitril/valsartan (the latter combination is contraindicated). Amlodipine interacts with CYP3A4 inhibitors such as clarithromycin and grapefruit, which may raise amlodipine levels by 30-50% and increase edema or hypotension risk. Simvastatin dose should be capped at 20 mg daily when co-administered with amlodipine due to increased myopathy risk per FDA labeling.

Real-World Evidence Beyond Randomized Trials

Randomized trials enroll selected populations. Real-world data from insurance claims and electronic health records add context.

Adherence

A 2019 analysis of U.S. Medicaid claims (N=approximately 180,000 antihypertensive initiators) found that CCBs including amlodipine had marginally better 12-month medication possession ratios than ACE inhibitors, likely driven by the cough discontinuation rate for ACE inhibitors. Mean 12-month MPR was 0.61 for ACE inhibitors vs 0.66 for CCBs in that dataset. [7]

Combination Prescribing Patterns

The most common two-drug antihypertensive combination in U.S. Practice is an ACE inhibitor or ARB paired with a CCB, reflecting both ASCOT-BPLA evidence and JNC 8 guidance. In the National Health and Nutrition Examination Survey (NHANES) 2015-2018 cycle, approximately 28% of treated hypertensive adults were on combination therapy, with the ACE inhibitor/CCB pair accounting for roughly 18% of all two-drug regimens. [8]

A Decision Framework for Choosing Between the Two Drugs

The following framework integrates trial evidence with clinical subgroup data:

| Patient Profile | Preferred Agent | Rationale | |---|---|---| | Black patient, no DM or CKD | Amlodipine (or thiazide) | ALLHAT: superior BP control; AHA/ACC guideline | | Type 2 DM with proteinuria >300 mg/day | Lisinopril | ACE inhibitor nephroprotection class effect | | Post-MI with reduced EF | Lisinopril | FDA-approved indication; ATLAS trial mortality benefit | | Stable angina | Amlodipine | Anti-anginal indication; CAMELOT trial | | Pregnancy suspected or planned | Neither; switch to labetalol or nifedipine | FDA categories X and C respectively | | ACE inhibitor cough | Switch to amlodipine or ARB | Bradykinin-mediated; class effect | | Edema from amlodipine | Switch to lisinopril or ARB | Dose-dependent; consider ACE/ARB | | Needs two-drug combo | Lisinopril 10-20 mg + amlodipine 5-10 mg | ASCOT-BPLA; JNC 8; AHA/ACC 2017 |

Should You Switch From Lisinopril to Amlodipine?

Switching is appropriate in specific circumstances, not as a default upgrade. Four clinical scenarios justify a switch.

Scenario 1: ACE Inhibitor Cough

If a patient on lisinopril develops persistent dry cough confirmed as drug-related, amlodipine 5 mg once daily is a reasonable alternative if no diabetic nephropathy or reduced EF indication mandates an ACE inhibitor. An ARB such as losartan 50 mg is also appropriate and preserves the renin-angiotensin axis blockade.

Scenario 2: Angioedema

Angioedema to lisinopril is a contraindication to all ACE inhibitors. Switching to an ARB is preferred over amlodipine if renin-angiotensin system blockade is desired (e.g., diabetic nephropathy). If no RAS-blocking indication exists, amlodipine is safe.

Scenario 3: Inadequate BP Control in Black Patients

If a Black patient on lisinopril monotherapy has uncontrolled BP without another compelling indication for ACE inhibition, adding or switching to a CCB or thiazide aligns with AHA/ACC 2017 race-specific guidance.

Scenario 4: Adding Amlodipine to Lisinopril

For most patients whose BP is not at goal on lisinopril alone, adding amlodipine 5 mg is preferable to switching. The ACE inhibitor/CCB combination addresses both neurohormonal and vascular resistance mechanisms and is supported by ASCOT-BPLA evidence showing a 23% stroke risk reduction with this strategy. [2]

Cost and Access

Both drugs are available as low-cost generics. At major U.S. Pharmacy chains, a 30-day supply of lisinopril 10 mg typically costs $4-$10 without insurance. Amlodipine 5 mg is similarly priced at $4-$12 for 30 tablets. Neither drug requires prior authorization for most commercial insurance formularies, and both appear on Tier 1 of the majority of Part D formularies. Cost should not drive the choice between these agents for most patients.

Summary of Guideline Positions

The AHA/ACC 2017 Hypertension Guideline recommends ACE inhibitors, ARBs, CCBs, and thiazide diuretics as first-line agents, explicitly noting that for Black adults without CKD, a CCB or thiazide is preferred. [3] JNC 8 (2014) similarly endorses CCBs and thiazides over ACE inhibitors as initial therapy in Black non-diabetic patients. For patients with CKD (any race), JNC 8 and AHA/ACC both recommend ACE inhibitor or ARB therapy regardless of whether a diuretic or CCB is also used. The ESC 2023 Hypertension Guidelines align with a preference for ACE inhibitor/CCB or ACE inhibitor/thiazide combinations as standard two-drug therapy for most patients in Europe. [9]